WallStSmart

Clover Health Investments Corp (CLOV)vsCVS Health Corp (CVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CVS Health Corp generates 16566% more annual revenue ($412.64B vs $2.48B). CVS leads profitability with a 1.2% profit margin vs -0.7%. CVS earns a higher WallStSmart Score of 67/100 (B-).

CLOV

Hold

38

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 6.7Quality: 4.3
Piotroski: 2/9Altman Z: -1.87

CVS

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 4.0Value: 8.7Quality: 5.5
Piotroski: 4/9Altman Z: 2.11
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CLOVUndervalued (+71.8%)

Margin of Safety

+71.8%

Fair Value

$7.26

Current Price

$4.82

$2.44 discount

UndervaluedFair: $7.26Overvalued
CVSUndervalued (+45.4%)

Margin of Safety

+45.4%

Fair Value

$141.12

Current Price

$94.66

$46.46 discount

UndervaluedFair: $141.12Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CLOV1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
55.6%10/10

Revenue surging 55.6% year-over-year

CVS5 strengths · Avg: 9.0/10
PEG RatioValuation
0.2210/10

Growing faster than its price suggests

EPS GrowthGrowth
188.8%10/10

Earnings expanding 188.8% YoY

Market CapQuality
$121.07B9/10

Large-cap with strong market position

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$5.65B8/10

Generating 5.7B in free cash flow

Areas to Watch

CLOV4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
3.8%3/10

Operating margin of 3.8%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-16.8%2/10

ROE of -16.8% — below average capital efficiency

CVS4 concerns · Avg: 3.3/10
P/E RatioValuation
25.1x4/10

Moderate valuation

Return on EquityProfitability
6.2%3/10

ROE of 6.2% — below average capital efficiency

Profit MarginProfitability
1.2%3/10

1.2% margin — thin

Operating MarginProfitability
3.9%3/10

Operating margin of 3.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : CLOV

The strongest argument for CLOV centers on Revenue Growth. Revenue growth of 55.6% demonstrates continued momentum.

Bull Case : CVS

The strongest argument for CVS centers on PEG Ratio, EPS Growth, Market Cap. PEG of 0.22 suggests the stock is reasonably priced for its growth.

Bear Case : CLOV

The primary concerns for CLOV are EPS Growth, Operating Margin, Piotroski F-Score.

Bear Case : CVS

The primary concerns for CVS are P/E Ratio, Return on Equity, Profit Margin. Thin 1.2% margins leave little buffer for downturns.

Key Dynamics to Monitor

CLOV profiles as a hypergrowth stock while CVS is a value play — different risk/reward profiles.

CLOV carries more volatility with a beta of 2.48 — expect wider price swings.

CLOV is growing revenue faster at 55.6% — sustainability is the question.

CVS generates stronger free cash flow (5.7B), providing more financial flexibility.

Bottom Line

CVS scores higher overall (67/100 vs 38/100). CLOV offers better value entry with a 71.8% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Clover Health Investments Corp

HEALTHCARE · HEALTHCARE PLANS · USA

Clover Health Investments, Corp. The company is headquartered in Franklin, Tennessee.

Visit Website →

CVS Health Corp

HEALTHCARE · HEALTHCARE PLANS · USA

CVS Health (previously CVS Corporation and CVS Caremark Corporation) is an American healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands. The company's headquarters is in Woonsocket, Rhode Island.

Visit Website →

Want to dig deeper into these stocks?